ReviewGynecologic oncology research and practice2017

PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers.

Mekonnen Sisay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.